Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis

Authors :: Mads A. Røpke
Amy S. Paller
Lisa A. Beck
Andrew Pink
Thomas Werfel
Lawrence Eichenfeld
Anders Rosholm
Hidehisa Saeki
Thomas Bieber
Source :: SKIN The Journal of Cutaneous Medicine. 5:s56
Publication Year :: 2021
Publisher :: National Society for Cutaneous Medicine, 2021.
Abstract: N/A

Subjects :: medicine.medical_specialty
Adult patients
business.industry
Microbial diversity
Placebo-controlled study
Atopic dermatitis
medicine.disease
Gastroenterology
Double blind
Internal medicine
Interleukin 13
Medicine
business
Tralokinumab

Full Text Access

Tools